Seeking Alpha
01 Jun 2026, 09:39 UTC · 22w ago
Verdict
Headline takes no side. We score GRCE +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 71% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA's CRL for GTx-104 was based solely on Chemistry, Manufacturing, and Controls (CMC) issues, with no objections to efficacy or safety.
More positive than 92% of claims this week
A scenario-weighted DCF model assigns a 75% probability of approval for GTx-104.
So whatA high probability of eventual approval supports a bullish long-term valuation despite the current regulatory delay.
Continue reading
5 related stories
More positive than 75% of claims this week
Grace Therapeutics has a $4 price target, implying a 57% upside from current levels.
More positive than 61% of claims this week
Which stocks this story touches
More positive than 71% of ticker scores this week
The company is rated as a Speculative Buy with significant implied upside and a high probability of FDA approval for GTx-104.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
58m ago
−28.4%
Price is moving against the score
$1.84 vs $2.57 close before publication (May 29) · not market-adjusted
GRCE chart →
